1
|
Liu J, Xu S, Huang C, Shen J, Yu S, Yu Y, Sun Q, Dai Q. Synthesis and activity evaluation of selenazole-coupled CPI-1 irreversible bifunctional inhibitors for botulinum toxin A light chain. Bioorg Med Chem Lett 2022; 73:128913. [PMID: 35914651 DOI: 10.1016/j.bmcl.2022.128913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 07/21/2022] [Accepted: 07/26/2022] [Indexed: 11/02/2022]
Abstract
A series of novel conjugates of benzoselenazole or selenazole and CPI-1 were designed, synthesized, and evaluated for inhibitory activities against the botulinum neurotoxin A (BoNT/A) light chain (LC) and BoNT/A in vivo. The results show that these compounds exhibit potent inhibitory activities to the LC with IC50 of 0.5-4.1 µM. The reaction kinetics and the mass spectra of the reaction products of LC with benzoselenazole- or selenazole- coupled CPI-1 demonstrate that the benzoselenazole group of most inhibitors is coupled to the LC of BoNT/A. These data indicate that the CPI-1 conjugates can inhibit both the active center of BoNT/A LC as well as Cys165, therefore functioning as irreversible bifunctional inhibitors. The detoxification activities in vivo show that one of the benzoselenazole-CPI-1 compounds prolongs the survival time of mice challenged by 2 × LD50 of BoNT/A. This work provides a new strategy to design potent antidotes of BoNT/A.
Collapse
|
2
|
Sen E, Kota KP, Panchal RG, Bavari S, Kiris E. Screening of a Focused Ubiquitin-Proteasome Pathway Inhibitor Library Identifies Small Molecules as Novel Modulators of Botulinum Neurotoxin Type A Toxicity. Front Pharmacol 2021; 12:763950. [PMID: 34646144 PMCID: PMC8503599 DOI: 10.3389/fphar.2021.763950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 09/14/2021] [Indexed: 01/18/2023] Open
Abstract
Botulinum neurotoxins (BoNTs) are known as the most potent bacterial toxins, which can cause potentially deadly disease botulism. BoNT Serotype A (BoNT/A) is the most studied serotype as it is responsible for most human botulism cases, and its formulations are extensively utilized in clinics for therapeutic and cosmetic applications. BoNT/A has the longest-lasting effect in neurons compared to other serotypes, and there has been high interest in understanding how BoNT/A manages to escape protein degradation machinery in neurons for months. Recent work demonstrated that an E3 ligase, HECTD2, leads to efficient ubiquitination of the BoNT/A Light Chain (A/LC); however, the dominant activity of a deubiquitinase (DUB), VCIP135, inhibits the degradation of the enzymatic component. Another DUB, USP9X, was also identified as a potential indirect contributor to A/LC degradation. In this study, we screened a focused ubiquitin-proteasome pathway inhibitor library, including VCIP135 and USP9X inhibitors, and identified ten potential lead compounds affecting BoNT/A mediated SNAP-25 cleavage in neurons in pre-intoxication conditions. We then tested the dose-dependent effects of the compounds and their potential toxic effects in cells. A subset of the lead compounds demonstrated efficacy on the stability and ubiquitination of A/LC in cells. Three of the compounds, WP1130 (degrasyn), PR-619, and Celastrol, further demonstrated efficacy against BoNT/A holotoxin in an in vitro post-intoxication model. Excitingly, PR-619 and WP1130 are known inhibitors of VCIP135 and USP9X, respectively. Modulation of BoNT turnover in cells by small molecules can potentially lead to the development of effective countermeasures against botulism.
Collapse
Affiliation(s)
- Edanur Sen
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
| | - Krishna P Kota
- Therapeutic Discovery Branch, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
| | - Rekha G Panchal
- Therapeutic Discovery Branch, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
| | - Sina Bavari
- Edge BioInnovation and Healion Bio, Frederick, MD, United States
| | - Erkan Kiris
- Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
| |
Collapse
|
3
|
Lin L, Olson ME, Sugane T, Turner LD, Tararina MA, Nielsen AL, Kurbanov EK, Pellett S, Johnson EA, Cohen SM, Allen KN, Janda KD. Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A. J Med Chem 2020; 63:11100-11120. [PMID: 32886509 PMCID: PMC7581224 DOI: 10.1021/acs.jmedchem.0c01006] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Botulinum neurotoxins have remarkable persistence (∼weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn2+ and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed.
Collapse
Affiliation(s)
- Lucy Lin
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Margaret E. Olson
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Takashi Sugane
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Lewis D. Turner
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Margarita A. Tararina
- Program in Biomolecular Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118, United States
| | - Alexander L. Nielsen
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Elbek K. Kurbanov
- Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Sabine Pellett
- Department of Bacteriology, University of Wisconsin, 1550 Linden Drive, Madison, Wisconsin 53706, United States
| | - Eric A. Johnson
- Department of Bacteriology, University of Wisconsin, 1550 Linden Drive, Madison, Wisconsin 53706, United States
| | - Seth M. Cohen
- Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
| | - Karen N. Allen
- Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, United States
| | - Kim D. Janda
- Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
4
|
Moreno da Costa D, Borja L, Verdugo C, Martinez J, Quintero C, Jaque P, Trofymchuk OS, Daniliuc CG, Cabrera AR, Rojas RS. Unexpected intramolecular N-arylcyano-β-diketiminate cyclization in new aminoquinoline derivative complexes of aluminium for CO2 fixation into cyclic carbonates. NEW J CHEM 2019. [DOI: 10.1039/c9nj02499a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
exo-Dig intramolecular cyclization of β-diketiminates allowed to obtain 4-amino-3-iminoquinolines ligands through a novel pathway. Al(III) complexes bearing these ligands where active towards the synthesis of cyclic carbonates from epoxides and CO2.
Collapse
Affiliation(s)
- David Moreno da Costa
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Luis Borja
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Camilo Verdugo
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Javier Martinez
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Celso Quintero
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Pablo Jaque
- Departamento de Química Orgánica y Fisicoquímica
- Facultad de Ciencias Químicas y Farmacéuticas
- Universidad de Chile
- Santiago
- Chile
| | | | | | - Alan R. Cabrera
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| | - Rene S. Rojas
- Departamento de Química Inorgánica
- Facultad de Química y de Farmacia
- Pontificia Universidad Católica de Chile
- Santiago
- Chile
| |
Collapse
|
5
|
Konstantinović J, Videnović M, Orsini S, Bogojević K, D’Alessandro S, Scaccabarozzi D, Terzić Jovanović N, Gradoni L, Basilico N, Šolaja BA. Novel Aminoquinoline Derivatives Significantly Reduce Parasite Load in Leishmania infantum Infected Mice. ACS Med Chem Lett 2018; 9:629-634. [PMID: 30034591 DOI: 10.1021/acsmedchemlett.8b00053] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Accepted: 05/04/2018] [Indexed: 01/21/2023] Open
Abstract
In this Letter, a detailed analysis of 30 4-aminoquinoline-based compounds with regard to their potential as antileishmanial drugs has been carried out. Ten compounds demonstrated IC50 < 1 μM against promastigote stages of L. infantum and L. tropica, and five compounds showed IC50 < 1 μM against intramacrophage L. infantum amastigotes. Two compounds showed dose-dependent enhancement of NO and ROS production by bone marrow-derived macrophages and remarkable reduction of parasite load in vivo, with advantage of being short-term and orally active. To the best of our knowledge, this is the first example of 4-amino-7-chloroquinoline derivatives active in Leishmania infantum infected mice.
Collapse
Affiliation(s)
- Jelena Konstantinović
- University of Belgrade, Faculty of Chemistry, Studentski trg 12-16, P.O. Box 51, 11158 Belgrade, Serbia
| | - Milica Videnović
- University of Belgrade, Faculty of Chemistry Innovative Centre, Studentski trg 12-16, 11158 Belgrade, Serbia
| | - Stefania Orsini
- Unit of Vector-borne Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Katarina Bogojević
- University of Belgrade, Faculty of Chemistry, Studentski trg 12-16, P.O. Box 51, 11158 Belgrade, Serbia
| | - Sarah D’Alessandro
- Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatrichè, Università degli Studi di Milano, Milan, Italy
| | - Diletta Scaccabarozzi
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
| | - Nataša Terzić Jovanović
- University of Belgrade, Institute of Chemistry, Technology, and Metallurgy, Njegoševa 12, 11000 Belgrade, Serbia
| | - Luigi Gradoni
- Unit of Vector-borne Diseases, Istituto Superiore di Sanità, Rome, Italy
| | - Nicoletta Basilico
- University of Belgrade, Faculty of Chemistry, Studentski trg 12-16, P.O. Box 51, 11158 Belgrade, Serbia
| | - Bogdan A. Šolaja
- University of Belgrade, Faculty of Chemistry, Studentski trg 12-16, P.O. Box 51, 11158 Belgrade, Serbia
- Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11158 Belgrade, Serbia
| |
Collapse
|